X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13846) 13846
Book Chapter (14) 14
Magazine Article (14) 14
Dissertation (6) 6
Book Review (3) 3
Conference Proceeding (3) 3
Publication (3) 3
Book / eBook (1) 1
Government Document (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7838) 7838
animals (7387) 7387
male (7022) 7022
indoles - pharmacology (5368) 5368
female (4669) 4669
indoles - administration & dosage (4172) 4172
indoles - therapeutic use (3470) 3470
rats (3355) 3355
pharmacology & pharmacy (2811) 2811
mice (2790) 2790
middle aged (2652) 2652
oncology (2192) 2192
adult (2147) 2147
aged (1978) 1978
dose-response relationship, drug (1883) 1883
indoles - adverse effects (1818) 1818
cancer (1608) 1608
treatment outcome (1429) 1429
neurosciences (1367) 1367
rats, sprague-dawley (1237) 1237
indoles - pharmacokinetics (1144) 1144
cell line, tumor (1105) 1105
administration, oral (1022) 1022
time factors (1012) 1012
analysis (978) 978
sunitinib (964) 964
indoles - chemistry (954) 954
expression (952) 952
disease models, animal (933) 933
care and treatment (916) 916
antineoplastic agents - therapeutic use (902) 902
research (898) 898
pyrroles - administration & dosage (895) 895
pyrroles - therapeutic use (888) 888
apoptosis (862) 862
biochemistry & molecular biology (854) 854
indoles (815) 815
rats, wistar (791) 791
double-blind method (720) 720
antineoplastic agents - administration & dosage (717) 717
therapy (670) 670
carcinoma, renal cell - drug therapy (656) 656
drug therapy (639) 639
indoles - metabolism (638) 638
apoptosis - drug effects (630) 630
kidney neoplasms - drug therapy (618) 618
tumors (617) 617
aged, 80 and over (614) 614
activation (611) 611
drug administration schedule (609) 609
indole (604) 604
inhibition (603) 603
medicine & public health (592) 592
chemotherapy (581) 581
antineoplastic agents - adverse effects (575) 575
cell biology (575) 575
mice, inbred c57bl (571) 571
enzyme inhibitors - pharmacology (569) 569
proteins (562) 562
pharmacokinetics (556) 556
pyrroles - adverse effects (553) 553
efficacy (552) 552
research article (549) 549
antineoplastic agents - pharmacology (540) 540
cell proliferation - drug effects (540) 540
in-vitro (536) 536
health aspects (534) 534
chemistry, medicinal (532) 532
antineoplastic combined chemotherapy protocols - therapeutic use (529) 529
cells (516) 516
metastasis (516) 516
angiogenesis (508) 508
drug therapy, combination (505) 505
pyrroles - pharmacology (493) 493
cells, cultured (491) 491
tyrosine kinase inhibitor (491) 491
pharmacology (489) 489
medicine (475) 475
kinases (471) 471
physiological aspects (469) 469
rodents (467) 467
endothelial growth-factor (462) 462
rat (461) 461
pharmacology/toxicology (459) 459
inflammation (456) 456
receptor (455) 455
clinical neurology (454) 454
antineoplastic agents (451) 451
survival (448) 448
in-vivo (445) 445
blood pressure - drug effects (444) 444
physiology (444) 444
drugs (442) 442
multidisciplinary sciences (441) 441
brain (440) 440
drug interactions (438) 438
niacinamide - analogs & derivatives (437) 437
signal transduction - drug effects (436) 436
medicine, research & experimental (433) 433
mutation (433) 433
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13489) 13489
Japanese (177) 177
Russian (106) 106
German (100) 100
French (61) 61
Chinese (49) 49
Spanish (22) 22
Italian (15) 15
Czech (10) 10
Hungarian (9) 9
Polish (8) 8
Danish (6) 6
Dutch (3) 3
Portuguese (3) 3
Norwegian (2) 2
Romanian (2) 2
Ukrainian (2) 2
Arabic (1) 1
Breton (1) 1
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
...). However, the potential for drug interactions with co‐administration of GSK2248761 and other antiretroviral medications or supportive medications is not known... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
The Lancet (British edition), ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1940 - 1948
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have... 
Double-Blind Method | Humans | yes | Pyridines/administration & dosage | Male | Pyrazoles/administration & dosage | Indoles/administration & dosage | Aminophenols/administration & dosage | Cystic Fibrosis Transmembrane Conductance Regulator/genetics | Cystic Fibrosis/drug therapy | Quinolones/administration & dosage | Adolescent | Sweat/chemistry | Female | Benzodioxoles/administration & dosage | Chloride Channel Agonists/administration & dosage | Drug Therapy, Combination | Child | Pyrrolidines/administration & dosage | MEDICINE, GENERAL & INTERNAL | GUIDELINES | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Sweat - chemistry | Pyridines - adverse effects | Quinolones - adverse effects | Benzodioxoles - adverse effects | Pyrazoles - adverse effects | Pyridines - administration & dosage | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Clinical trials | Cystic fibrosis | Ivacaftor | Genetic aspects | Infections | Modulators | Defects | Quality of life | Resistance | Proteins | Randomization | Chloride | Chlorides | Fibrosis | Conductance | Mutation | Safety | Sweat | Active control
Journal Article
Theranostics, ISSN 1838-7640, 2016, Volume 6, Issue 7, pp. 1031 - 1042
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 19, pp. 1809 - 1819
Triple treatment with elexacaftor, tezacaftor, and ivacaftor in patients with cystic fibrosis who had one Phe508del allele and a minimal-function mutation... 
TRANSMEMBRANE CONDUCTANCE REGULATOR | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | EXACERBATIONS | FEV1 | POTENTIATOR | DECLINE | Cystic Fibrosis - physiopathology | Humans | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Chloride Channel Agonists - adverse effects | Benzodioxoles - administration & dosage | Aminophenols - adverse effects | Indoles - administration & dosage | Forced Expiratory Volume | Sweat - chemistry | Young Adult | Pyridines - adverse effects | Quinolones - adverse effects | Adult | Benzodioxoles - adverse effects | Female | Child | Pyrazoles - adverse effects | Pyridines - administration & dosage | Double-Blind Method | Genotype | Chlorides - analysis | Pyrazoles - administration & dosage | Quinolones - administration & dosage | Indoles - adverse effects | Chloride Channel Agonists - administration & dosage | Cystic Fibrosis - genetics | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Mutation | Aminophenols - administration & dosage | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Drug therapy | Patient outcomes | Statistical analysis | Stock options | Clinical trials | Patients | Clinical outcomes | Quality of life | Proteins | Collaboration | Conductance | Genotypes | Pharmaceuticals
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article